Under-eye concerns drive more aesthetic consultations than almost any other facial area, and for good reason - the periorbital zone is thin-skinned, structurally complex, and unforgiving of the wrong treatment. For years, the main injectable choices were platelet-rich plasma and hyaluronic acid tear-trough filler. Polynucleotides - often abbreviated PN or PDRN - have shifted that conversation. They are now the most discussed biostimulator alternative in periorbital aesthetics, yet most available patient information blurs them together with fillers, misrepresents what they fix, or skips the clinical evidence entirely. This guide works through the biology, the evidence, and the decision logic so a patient can arrive at any consultation with a clear picture of whether PN belongs in their plan.
What Polynucleotides Are and Where They Come From
Polynucleotides are purified long-chain DNA fragments extracted from salmon or trout sperm through enzymatic digestion and high-purity processing. That process strips away cellular material entirely, leaving only the nucleotide strand. The result is a stable injectable with no fish proteins, no intact cells, and no genetic material that could integrate into human tissue.
Biocompatibility is high despite the non-human origin. Nucleotide sequences share enough structural similarity across species that the human immune system does not read the purified fragments as foreign - there is no IgE-mediated allergy response in the vast majority of patients. Patients with fish allergies are routinely screened, but the allergy risk of PN is distinct from fish protein allergy and must be evaluated separately.
The term PDRN - polydeoxyribonucleotide - refers to a defined subfraction of the broader PN family. Where PN spans a wide range of chain lengths and molecular weights, PDRN conventionally refers to shorter fragments - defined in the scientific literature primarily by molecular weight below approximately 1,500 kDa rather than by a fixed base-pair count. Shorter chains penetrate tissue more readily; longer chains may remain more superficial. Products marketed as PDRN and products marketed as PN can therefore differ in tissue behavior even if used interchangeably in conversation. When evaluating a provider's protocol, the molecular weight distribution of the specific preparation is worth asking about.

The Cellular Mechanism: Why This Is Not a Filler
The key target is the adenosine A2A receptor on the surface of fibroblasts - the cells responsible for producing extracellular matrix in skin. When polynucleotide fragments bind this receptor, they trigger a signaling cascade through cAMP and its downstream effectors PKA and CREB. What that cascade drives:
- Fibroblast proliferation - more matrix-producing cells in the treated zone
- Upregulated synthesis of collagen type I, the structural backbone of dermis, and collagen type III, the more pliable early-repair collagen
- Increased elastin production, contributing to skin recoil and firmness
- Angiogenesis - new capillary formation that improves local microcirculation
None of these outputs add bulk volume. The dermis thickens because its own structural components are rebuilt, not because a foreign material occupies space beneath it. This is why results take weeks to appear and peak at roughly three months - and why PN cannot substitute for a volumizer in a patient with true hollowing. That distinction is the central fact in every treatment decision that follows.
What PN Can Actually Fix in the Periorbital Zone
Crepey, Thin Lower-Eyelid Skin
The lower eyelid has some of the thinnest skin on the face. As dermal collagen degrades over time, the skin loses the scaffolding that holds it smooth. PN targets this directly: fibroblast activation rebuilds dermal thickness, and the combination of new collagen and elastin restores a surface that is less prone to crumpling. This is one of the strongest and most consistent indications for PN in this zone.
Vascular Dark Circles
Not all dark circles have the same cause, and PN only addresses one specific type. The vascular subtype occurs when the capillary network under the lower-eyelid skin is dense enough, and the skin thin enough, that the red-blue color of vessels shows through. PN addresses this from both directions: dermal thickening reduces optical transparency, and angiogenesis-driven remodeling improves microcirculatory flow, reducing the stagnant pooling that makes venous color more visible. Patients with discoloration that has a blue or purple cast, that worsens after poor sleep, and that is not simply a shadow cast by hollowing are realistic PN candidates for this concern.
Fine Lines: Crow's Feet and Lower-Lid Creases
Early crow's feet and lower-lid horizontal creases form in part because thinning dermis can no longer absorb and distribute the mechanical stress of orbicularis oculi muscle contraction. Rebuilding dermal substance with new collagen and elastin reduces the depth and definition of these lines over the course of the treatment series. The effect is real and measurable, though it is a remodeling response - moderate and gradual, not the immediate line-erasing effect of botulinum toxin.
Beyond these specific presentations, reduced hydration retention, dull surface texture, and mild dyspigmentation from prior sun exposure also respond to PN-driven matrix rebuilding. The head-to-head clinical data confirm PN outperforms HA filler on surface roughness and pore appearance - an unsurprising result given that filler adds volume while PN rebuilds dermal architecture from within.

What PN Cannot Fix and Why
- Deep tear-trough hollowing. When periorbital fat atrophies and the tear-trough ligament becomes more visible, there is a volume deficit that PN cannot fill. The mechanism produces no structural bulk. HA tear-trough filler or fat grafting is the appropriate approach for this presentation.
- Herniated fat-pad bags. Bulging from fat-pad prolapse through the orbital septum requires either surgical repositioning or removal via lower blepharoplasty. PN may improve the skin quality over the bag, but it will not reduce the bag itself.
- Shadow-based dark circles. When discoloration under the eye is a shadow cast by hollowing or fat-pad prominence, improving skin quality has no effect on the shadow. Volume correction or surgical correction is the relevant treatment.
- Significant dermatochalasis. Moderate-to-severe excess eyelid skin is a surgical finding. PN improves skin quality and mildly tightens through new collagen production, but it cannot excise redundant skin or reliably correct functional lid ptosis.
- Brown pigmentary dark circles. Melanin deposition in the periorbital skin responds better to topical depigmenting agents or laser than to any injectable biostimulator, including PN.
What the Clinical Literature Actually Shows
Three pieces of evidence form the core of what is currently known about periorbital PN in well-designed studies.
A 2026 prospective observational cohort by Ziade and colleagues, published in the Journal of Cosmetic Dermatology, enrolled 42 patients aged 25 to 65 with Glogau grade II-III periorbital rhytides across Fitzpatrick skin types I through IV. Patients received two intradermal PN injection sessions. Clinician appraisal scores for lower-eyelid lines and crow's feet improved significantly at every follow-up point, with the greatest effect size and highest patient satisfaction at three months - the timeframe that aligns with peak collagen remodeling output.
A 2026 systematic review published in the Aesthetic Surgery Journal Open Forum analyzed 219 periorbital PN-treated patients. The safety finding was notable: no serious complications, no delayed adverse events, no nodules, no prolonged edema, and no Tyndall-like discoloration at any follow-up visit. Mild transient swelling and bruising were the only adverse events reported.
Evaluated patients in the reviewed studies showed moderate improvement in periorbital wrinkle appearance at six-month follow-up - a finding the review authors interpreted as consistent with PN acting as a skin-quality treatment rather than a volumizing one.
Paraphrased from: Efficacy of Polynucleotides in Periorbital Rejuvenation: A Systematic Review, Aesthetic Surgery Journal Open Forum, 2026
A 2026 head-to-head comparison in the Journal of Clinical Medicine directly compared PN and HA filler for under-eye rejuvenation. PN outperformed HA on skin-quality measures including surface roughness, pore size, elasticity, and hydration, and maintained those improvements longer. HA filler produced superior immediate volumetric correction of hollowing. The two treatments are not competing alternatives for the same problem - they address different anatomical components of under-eye aging and are often appropriate in the same patient at the same time.

PN Versus HA Tear-Trough Filler: A Direct Comparison
| Factor | PN / PDRN | HA Tear-Trough Filler |
|---|---|---|
| Primary effect | Dermal remodeling, skin quality | Immediate volumetric correction |
| Onset of result | Gradual, peak at ~3 months | Immediate, visible same session |
| Tyndall-effect risk | None - no refractive hydrogel deposit | Present if placed too superficially |
| Reversibility | Not reversible - no dissolving enzyme exists | Reversible with hyaluronidase |
| Malar edema risk | Markedly lower - no hygroscopic effect | Known risk, especially with higher volumes |
| Best indication | Crepey skin, fine lines, vascular dark circles | True tear-trough hollowing, volume deficit |
The Tyndall effect deserves particular attention because it is a risk that competitor content almost never mentions in this context. This blue-tinted discoloration appears when HA filler is placed too superficially under the thin lower-eyelid skin, where the product creates a refractive deposit visible through the skin. PN carries no equivalent risk because it does not form a hydrogel mass - it integrates at the cellular level. This makes the periorbital zone less technically unforgiving with PN than with HA filler, and it is part of why providers who have encountered Tyndall complications with HA in this zone often prefer PN for the skin-quality component of treatment.
The reversibility difference is a material consideration that patients rarely hear explained clearly. HA filler can be dissolved with hyaluronidase if the result is unsatisfactory or complications arise. Polynucleotides are DNA strands; hyaluronidase specifically cleaves glycosaminoglycan bonds and has no effect on nucleotide chains. If a patient is dissatisfied with PN results, they wait for natural metabolism to clear the product over months. There is no rapid correction available.
PN Versus PRP for the Periorbital Zone
Both PRP and PN biostimulate - both prompt the body's own cells to build tissue - but through entirely different mechanisms, and the practical differences matter for decision-making.
- Source of action. PRP concentrates the patient's own platelets and delivers the growth factors those platelets release upon activation - primarily PDGF, TGF-beta, and VEGF. PN provides exogenous adenosine receptor ligands derived from salmon DNA. One draws on autologous biology; the other delivers a consistent external molecule that activates a specific receptor pathway.
- Allergy and immune response. PRP carries essentially zero external allergy risk because it derives entirely from the patient's own blood. PN requires screening for the rare patient who may react to salmon-derived material, though reaction rates in clinical literature are very low.
- Consistency of dose. PRP output varies with the patient's baseline platelet count, the centrifugation protocol, and the activation method. A patient with low platelet counts produces a weaker preparation. PN delivers a known molecular quantity per milliliter of product regardless of patient biology - the dose is consistent session to session.
- Procedural requirements. PRP requires a blood draw and centrifugation immediately before each session, adding procedural time and equipment. PN arrives ready to inject.
The two treatments can be combined, and several practices in periorbital aesthetics use them together - PN for its receptor-driven collagen stimulus, PRP for the broader growth-factor environment that may enhance healing. Neither replaces the other; they address the biostimulation goal through complementary pathways.
Treatment Protocol, Injection Technique, and What to Expect Session by Session
The standard induction series for periorbital PN runs three to four sessions. The sequence below reflects the protocol used in the clinical literature:
- Initial consultation and baseline photography. The injector documents the specific under-eye concerns, skin type, and prior procedures. Realistic outcome expectations are established before treatment begins.
- Session one. PN is placed intradermally in the mid-dermis using a fine-gauge needle - typically 30 or 32 gauge - in a linear threading or papule technique. The critical principle is small aliquots per injection point. The product swells transiently before it integrates into tissue; large boluses or deep placement in this zone create visible lumps that resolve but are uncomfortable in the interim.
- Sessions two and three follow at two-to-four-week intervals. Some patients require a fourth induction session before moving to maintenance, particularly those with more advanced rhytides or thinner baseline skin.
- Post-induction waiting period. The most important outcome window is at three months post-induction, when collagen remodeling has had time to mature. Patients who evaluate results at four to six weeks often underestimate the final outcome.
- Maintenance phase. Most patients benefit from maintenance sessions every four to six months to sustain the remodeling response. Those with more advanced skin aging may require more frequent intervals.
Post-injection mild swelling and bruising at injection points is expected and typically resolves within a few days. The periorbital zone bruises readily given its vascularity. Anticoagulants and supplements that affect platelet function are worth reviewing with an injector before each session.
Patient Selection, Red Flags, and When to See an Oculoplastic Surgeon First
The clearest PN candidates are patients with thin or crepey lower-eyelid skin, blue-purple vascular dark circles that worsen with fatigue, fine crow's feet and lower-lid creases in the early-to-moderate range, or prior malar edema from HA filler who want skin-quality improvement without volumizing. Patients who have no significant volume deficit and whose main concern is skin texture and tone are the core indication.
Patients less likely to get adequate correction from PN alone include those with deep tear-trough hollowing, significant fat-pad bags, or moderate-to-severe excess eyelid skin. For these presentations, PN may improve skin quality at the margins but will not resolve the structural concern driving the visible change.
An oculoplastic surgeon evaluation is worth pursuing before any injectable - including PN - when there is significant eyelid skin excess that may affect vision, when lower-lid fat-pad bags are prominent, when there is any lid malposition, or when the patient has had prior eyelid surgery with altered anatomy. Attempting to build skin quality over a structural problem that needs surgical correction does not eliminate the need for surgery and may add cost without resolving the core concern.
As of 2026, no polynucleotide product carries an FDA indication specifically for periorbital treatment in the United States. Several PN products - including Rejuran, Plinest, and Nucleofill - hold regulatory clearance in South Korea, the European Union, and the United Kingdom, and are used off-label in US aesthetic practices. Patients seeking treatment at Florida clinics should ask their injector about the specific product being used, its clearance status, and their training in periorbital PN technique specifically. The clinical evidence reviewed here comes from practices using standardized intradermal injection technique - not improvised protocol - and the distinction matters for both safety and outcome.
Frequently Asked Questions
How long do PN results in the under-eye area last?
The remodeling response from an induction series peaks at roughly three months and generally holds for several months before gradual regression begins. Most patients benefit from maintenance sessions every four to six months to sustain the improvement. Individual variation is significant depending on baseline skin quality, age, and cumulative sun damage.
Can PN and HA tear-trough filler be used together?
Yes - and because they address different problems, combining them is often appropriate. HA filler corrects volume deficit in the tear trough while PN rebuilds skin quality in the lower eyelid. Some providers stagger the two treatments by a few weeks; others combine them in a single session. The specifics depend on the patient's presentation and the injector's technique preference.
Is there any risk of Tyndall effect with PN under the eyes?
No. The Tyndall effect - a blue-grey discoloration under thin skin - occurs when HA filler creates a refractive hydrogel deposit near the skin surface. PN does not form a hydrogel mass; it integrates at the cellular level without creating an optical deposit. This is one reason practitioners favor PN for shallow intradermal placement in the periorbital zone, where the skin is too thin to safely conceal superficially placed HA filler.
Can PN results be reversed if I am unhappy with the outcome?
No reversal agent exists for polynucleotides. Hyaluronidase dissolves HA filler but has no effect on DNA strands. If the result is unsatisfactory, the product metabolizes naturally over months. This is an important distinction from HA filler, which can be dissolved rapidly, and it is worth weighing carefully before proceeding with PN treatment.
Who should not receive PN injections near the eyes?
Patients with active skin infection in the treatment zone, those who are pregnant or breastfeeding, and those with known hypersensitivity to salmon-derived products should not receive PN. Patients on anticoagulant therapy have a higher bruising risk in this vascular area and should discuss that history with their injector before proceeding. Anyone with a structural eyelid finding - functional lid ptosis, prominent fat herniation, or prior eyelid surgery with altered anatomy - should have an oculoplastic surgeon evaluation before any injectable treatment.
General information only, not medical advice. Individual anatomy and healing vary. See the disclaimer.